The pharma stock is up around 17% this year.
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
GlobalData on MSN
Vertex signs agreement to acquire Crinetics for $10bn
The acquisition is expected to close in the third quarter of 2026.
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...
Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...
With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...
Vertex Pharmaceuticals Incorporated VRTX on Monday agreed to acquire Crinetics Pharmaceuticals Inc. CRNX for $85 per share in ...
Vertex AI is a comprehensive machine learning platform by Google Cloud, provides an all-inclusive suite of tools and resources for the creation, deployment, and customization of machine learning ...
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Sundar Pichai introduced Vertex AI to the world during the Google I/O 2021 conference last year, placing it against managed AI platforms such as Amazon Web Services (AWS) and Azure in the global AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results